[
    [
        {
            "time": "2022-10-15",
            "original_text": "Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients",
            "features": {
                "keywords": [
                    "Tirzepatide",
                    "Non-Inferior",
                    "Insulin Glargine",
                    "Type 2 Diabetes"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly's Tirzepatide Non-Inferior To Titrated Insulin Glargine In Type 2 Diabetes Patients",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2022-10-15",
            "original_text": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial",
            "features": {
                "keywords": [
                    "tirzepatide",
                    "achieves",
                    "primary",
                    "secondary",
                    "outcomes",
                    "insulin glargine",
                    "type 2 diabetes",
                    "cardiovascular risk",
                    "SURPASS-4"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]